Evidence map›Paper›PMID 33423010›Full record

ArticleJournal of the neurological sciences2021

Evaluation of a screening tool for the identification of neurological disorders in rural Uganda.

Andy Tran, Kiran T Thakur, Noeline Nakasujja, Gertrude Nakigozi, Alice Kisakye, James Batte, Richard Mayanja, Aggrey Anok, Ronald H Gray, Maria J Wawer and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the neurological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Andy TranUniversity of Iowa Carver College of Medicine, Iowa City, IA, USA.
Kiran T ThakurDepartment of Neurology, Columbia University, New York City, NY, USA.
Noeline NakasujjaDepartment of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Alice KisakyeRakai Health Sciences Program, Kalisizo, Uganda.
James BatteRakai Health Sciences Program, Kalisizo, Uganda.
Richard MayanjaRakai Health Sciences Program, Kalisizo, Uganda.
Aggrey AnokRakai Health Sciences Program, Kalisizo, Uganda.
Ronald H GrayDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Maria J WawerDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Leah H RubinDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ned SacktorDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Deanna SaylorDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, University Teaching Hospital, Lusaka, Zambia. Electronic address: deanna@jhmi.edu.
Rakai Health Sciences Program · UGJohns Hopkins University · USColumbia University · USJohns Hopkins Medicine · USMakerere University · UGUniversity of Iowa · USUniversity Teaching Hospital · ZM

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Barbara Stauch Slusher · 2006 to 2026
$33.2M
Research Education Program for Residents and Fellows in Neurology - PorrasR25NS065729 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HILLIS, ARGYE E. · 2009 to 2024
$3.3M
Neurologic Sequelae of HIV Subtype A and D Infection and ART Rakai UgandaR01MH099733 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C, WAWER, MARIA J · 2013 to 2017
$3.0M
Translational Research in Neuro-AIDS and Mental HealthR25MH080661 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MCARTHUR, JUSTIN CHARLES. · 2007 to 2019
$2.9M
Mental Health and Cognition in HIV Infection in Rakai UgandaR01MH120693 · NIMH · JOHNS HOPKINS UNIVERSITY · PI PAUL, ROBERT HARRIS, RUBIN, LEAH HELANE · 2019 to 2023
$2.9M
Research Education Program for Residents and Fellows in NeurologyUE5NS065729 · NINDS · JOHNS HOPKINS UNIVERSITY · PI CHETAN BETTEGOWDA, Argye E. Hillis · 2025 to 2026
$606k
NIAID NIH HHS P30 AI094189NIMH NIH HHS P30 MH075673NIMH NIH HHS R01 MH099733NIMH NIH HHS R01 MH120693NIMH NIH HHS R25 MH080661NINDS NIH HHS L30 NS088658NINDS NIH HHS R25 NS065729NINDS NIH HHS UE5 NS065729
6 · The paper itself

Abstract

backgroundNeurological disorders are common in sub-Saharan African, but accurate neuroepidemiologic data are lacking from the region. We assessed a neuroepidemiological screening tool in a rural Ugandan cohort with high HIV prevalence.

methodsParticipants were recruited from the Rakai Neurology Study in rural Rakai District, Uganda. A nurse administered the tool and a sociodemographic survey. 100 participants returned for validation examinations by a neurologist (validation cohort). The diagnostic utility and validity of the instrument were calculated and characteristics of those with and without neurological disorders compared.

resultsThe tool was administered to 392 participants, 48% female, 33% people with HIV, average age 35.1 ± 8.5 years. 33% of the study cohort screened positive for neurologic disorders. These participants were older [mean (SD): 38.3 (9.7) vs. 33.5 (7.1) years, p < 0.001], had a lower Karnofsky score [89.8 (8.4) vs. 93.9 (7.5), p < 0.001] and had a lower body mass index [21.8 (3.3) vs. 22.8 (3.7), p = 0.007] than those who screened negative. Amongst the validation cohort, 54% had a neurological abnormality of which 46% were symptomatic. The tool was 57% sensitive and 74% specific for detecting any neurological abnormality and 80% sensitive and 69% specific for symptomatic abnormalities.

conclusionsWe found a lower sensitivity and similar specificity for the screening tool compared with two previous studies. The lower validity in this study was likely due in part to the high percentage of asymptomatic neurological abnormalities detected. This screening tool will require further refinement and cultural contextualization before it can be widely implemented across new populations.

Indexed as

HIV InfectionsNervous System DiseasesAdultCohort StudiesFemaleHumansMaleMass ScreeningPrevalenceRural PopulationUgandaAfricaGlobal neurologyNeuroepidemiologyScreening toolUganda

Identifiers

PMID33423010
PMCPMC7914201
OpenAlexW3118168658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.